Jomed struggles as bankruptcy looms
This article was originally published in Clinica
Executive Summary
Jomed, which is listed on the Swiss stock market but headquartered in the Netherlands, is facing possible bankruptcy after its creditors refused to sign a joint standstill agreement. The company's outlook has taken a rapid turn for the worse since it admitted discrepancies in its accounting earlier this month (see Clinica No 1041, p 9).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.